Jove
Visualize
Contact Us

Related Experiment Videos

Immusorba TR and PH.

Noriko Hirata1, Toshiji Kuriyama, Naokuni Yamawaki

  • 1Development and Scientific Affairs Department, Asahi Medical Co., Tokyo, Japan. hirata.nb@om.asahi-kasei.co.jp

Therapeutic Apheresis and Dialysis : Official Peer-Reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
|August 19, 2003
PubMed
Summary

Immusorba TR and Immusorba PH are novel adsorbents using non-biological ligands to remove pathogenic autoantibodies. These treatments show promise for autoimmune neurological and collagen diseases, with potential for broader applications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Double filtration plasmapheresis: Review of current clinical applications.

Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy·2020
Same author

Modification of the Dialysate Port of Plasma Separators for Safe Blood Purification in Japan.

Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy·2018
Same author

Plasma separation using a membrane.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis·2017
Same author

Immunoadsorption using Immusorba TR and PH.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis·2017
Same author

Central line-associated bloodstream infection: is the hospital epidemiology of methicillin-resistant Staphylococcus aureus relevant?

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy·2010
Same author

Short-term efficacy of tacrolimus ointment and impact on quality of life.

Pediatrics international : official journal of the Japan Pediatric Society·2009
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Biomaterials Science
  • Immunology
  • Medical Technology

Background:

  • Pathogenic autoantibodies play a crucial role in autoimmune diseases.
  • Current treatments for autoimmune conditions have limitations.
  • Development of effective autoantibody removal strategies is needed.

Purpose of the Study:

  • To introduce Immusorba TR (IM-TR) and Immusorba PH (IM-PH) as novel adsorbents for pathogenic autoantibody removal.
  • To highlight the clinical applications and potential of these non-biological adsorbents.

Main Methods:

  • Immusorba adsorbents are based on polyvinyl alcohol gel.
  • Tryptophan and phenylalanine serve as immobilized affinity ligands in IM-TR and IM-PH, respectively.
  • Clinical application in autoimmune disease treatment.

Related Experiment Videos

Main Results:

  • IM-TR is clinically used for autoimmune neurological diseases like myasthenia gravis and Guillain-Barre syndrome.
  • IM-PH treats neurological diseases (GBS, multiple sclerosis) and collagen diseases (rheumatoid arthritis, systemic lupus erythematosus).
  • Immusorba shows broad affinity for various autoantibodies.

Conclusions:

  • Immusorba TR and PH are effective non-biological adsorbents for pathogenic autoantibody removal.
  • These adsorbents have established clinical utility in neurological and collagen diseases.
  • Future applications are expected for broader autoimmune disease treatment and understanding disease mechanisms.